ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : -6 مورد

Tofacitinib: Pediatric drug information

Tofacitinib: Pediatric drug information
2025© UpToDate, Inc. and its affiliates and/or licensors. All Rights Reserved.
For additional information see "Tofacitinib: Drug information" and "Tofacitinib: Patient drug information"

For abbreviations, symbols, and age group definitions show table
ALERT: US Boxed Warning
Serious infections:

Patients treated with tofacitinib are at increased risk of developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant immunosuppressants, such as methotrexate or corticosteroids.

If a serious infection develops, interrupt tofacitinib until the infection is controlled.

Reported infections include:

• Active tuberculosis (TB), which may present with pulmonary or extrapulmonary disease. Patients should be tested for latent TB before tofacitinib use and during therapy. Treatment for latent infection should be initiated prior to tofacitinib use.

• Invasive fungal infections, including cryptococcosis and pneumocystosis. Patients with invasive fungal infections may present with disseminated rather than localized disease.

• Bacterial, viral (including herpes zoster), and other infections due to opportunistic pathogens.

The risks and benefits of treatment with tofacitinib should be carefully considered prior to initiating therapy in patients with chronic or recurrent infection.

Patients should be closely monitored for the development of signs and symptoms of infection during and after treatment with tofacitinib, including the possible development of TB in patients who tested negative for latent TB infection prior to initiating therapy.

Mortality:

In a large, randomized, postmarketing safety study in rheumatoid arthritis (RA) patients ≥50 years of age with ≥1 cardiovascular risk factor comparing tofacitinib 5 mg twice a day or tofacitinib 10 mg twice a day to tumor necrosis factor (TNF) blockers, a higher rate of all-cause mortality, including sudden cardiovascular death, was observed with tofacitinib 5 mg twice a day or tofacitinib 10 mg twice a day. Tofacitinib 10 mg twice daily (or tofacitinib XR 22 mg once daily) dosage is not recommended for the treatment of RA or psoriatic arthritis (PsA).

Malignancies:

Malignancies, including lymphomas and solid tumors, have occurred in patients treated with tofacitinib and other Janus kinase inhibitors used to treat inflammatory conditions. In RA patients, a higher rate of malignancies (excluding non-melanoma skin cancer [NMSC]) was observed in patients treated with tofacitinib 5 mg twice a day or tofacitinib 10 mg twice a day compared TNF blockers.

Lymphomas and lung cancers were observed at a higher rate in patients treated with tofacitinib 5 mg twice a day or tofacitinib 10 mg twice a day in RA patients compared to those treated with TNF blockers. Patients who are current or past smokers are at additional increased risk.

Epstein-Barr virus-associated posttransplant lymphoproliferative disorder has been observed at an increased rate in renal transplant patients treated with tofacitinib and concomitant immunosuppressive medications.

Major adverse cardiovascular events:

RA patients ≥50 years of age with ≥1 cardiovascular risk factor, treated with tofacitinib 5 mg twice daily or tofacitinib 10 mg twice daily, had a higher rate of major adverse cardiovascular events (defined as cardiovascular death, myocardial infarction, and stroke), compared to those treated with TNF blockers. Patients who are current or past smokers are at additional increased risk. Discontinue tofacitinib in patients that have experienced a myocardial infarction or stroke.

Thrombosis:

Thrombosis, including pulmonary embolism, deep venous thrombosis, and arterial thrombosis, have occurred in patients treated with tofacitinib and other Janus kinase inhibitors used to treat inflammatory conditions. Many of these events were serious and some resulted in death. RA patients ≥50 years of age with ≥1 cardiovascular risk factor treated with tofacitinib 5 mg twice daily or tofacitinib 10 mg twice daily compared to TNF blockers had an observed increase in incidence of these events. Avoid tofacitinib in patients at risk. Discontinue tofacitinib and promptly evaluate patients with symptoms of thrombosis.

Brand Names: US
  • Xeljanz;
  • Xeljanz XR
Brand Names: Canada
  • AURO-Tofacitinib;
  • JAMP-Tofacitinib;
  • PMS-Tofacitinib;
  • TARO-Tofacitinib;
  • Xeljanz;
  • Xeljanz XR
Therapeutic Category
  • Antirheumatic Miscellaneous;
  • Antirheumatic, Disease Modifying;
  • Janus Associated Kinase Inhibitor
Dosing: Pediatric

Note: Oral solution and extended-release tablets are not bioequivalent and should not be substituted on a mg:mg basis; oral solution and immediate-release tablet may be converted mg:mg (5 mg oral solution may be switched to 5 mg immediate-release tablet). Assess baseline CBC; do not initiate therapy in patients with an absolute lymphocyte count <500 cells/mm3, ANC <1,000 cells/mm3, or hemoglobin <9 g/dL.

Juvenile idiopathic arthritis, polyarticular course

Juvenile idiopathic arthritis, polyarticular course:

Children ≥2 years weighing ≥10 kg and Adolescents: Oral:

10 to <20 kg: Oral solution (1 mg/mL): 3.2 mg twice daily.

20 to <40 kg: Oral solution (1 mg/mL): 4 mg twice daily.

≥40 kg: Oral solution (1 mg/mL) or immediate-release tablet: 5 mg twice daily.

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosage adjustment for toxicity: Children ≥2 years and Adolescents: Oral: Oral solution, immediate-release tablets:

Infection: If a patient develops a serious infection, interrupt treatment until the infection is controlled.

Anemia (hemoglobin <8 g/dL or decrease >2 g/dL): Interrupt therapy until hemoglobin values have normalized.

Lymphopenia (lymphocytes <500 cells/mm3) confirmed by repeat evaluation: Discontinue therapy.

Neutropenia:

ANC between 500 to 1,000 cells/mm3: Interrupt therapy until ANC >1,000 cells/mm3.

ANC <500 cells/mm3: Discontinue therapy.

Dosing: Kidney Impairment: Pediatric

Children ≥2 years and Adolescents: Oral: Oral solution, immediate-release tablets:

Mild kidney impairment: No adjustment necessary.

Moderate to severe kidney impairment: Reduce dose frequency to once daily.

Hemodialysis: Administer dose after dialysis session on dialysis days; if dose administered before session, a supplemental dose post-dialysis is not recommended.

Dosing: Liver Impairment: Pediatric

Children ≥2 years and Adolescents: Oral: Oral solution, immediate-release tablet:

Mild hepatic impairment: No adjustment necessary.

Moderate hepatic impairment: Reduce dose frequency to once daily.

Severe hepatic impairment: Use is not recommended.

Dosing: Adult

(For additional information see "Tofacitinib: Drug information")

Note: ER tablets and oral solution are not interchangeable or substitutable. When transitioning from IR tablet to ER tablet, begin ER tablet the day following the last dose of IR tablet. Do not initiate therapy in patients with an absolute lymphocyte count <500 cells/mm3, ANC <1,000 cells/mm3, or hemoglobin <9 g/dL.

Ankylosing spondylitis

Ankylosing spondylitis: Oral:

IR tablet: 5 mg twice daily.

ER tablet: 11 mg once daily.

COVID-19, hospitalized patients

COVID-19, hospitalized patients (alternative agent) (off-label use):

Note: For use only as an alternative to baricitinib, for hospitalized patients with significant oxygen requirements (eg, high-flow oxygen, noninvasive ventilation, mechanical ventilation, extracorporeal membrane oxygenation) and those with lower but increasing oxygen requirements and evidence of systemic inflammation (Ref).

Oral: IR tablet: 10 mg twice daily, as part of an appropriate combination regimen, for 14 days or until hospital discharge, whichever is earlier (Ref).

Psoriasis

Psoriasis (off-label): Oral: IR tablet: 5 to 10 mg twice daily (Ref).

Psoriatic arthritis

Psoriatic arthritis (use in combination with nonbiologic disease-modifying antirheumatic drugs): Oral:

IR tablet: 5 mg twice daily.

ER tablet: 11 mg once daily.

Rheumatoid arthritis

Rheumatoid arthritis:

Note: For use as adjunctive therapy with nonbiologic disease-modifying antirheumatic drugs (DMARDs) in patients who have not met treatment goals despite maximally tolerated methotrexate therapy; may also be used off label as an alternative to methotrexate in DMARD-naive patients with moderate to high disease activity (Ref).

Oral:

IR tablet: 5 mg twice daily.

ER tablet: 11 mg once daily.

Ulcerative colitis

Ulcerative colitis (alternative agent): Oral:

IR tablet:

Induction: 10 mg twice daily for at least 8 weeks; based on therapeutic response, may continue 10 mg twice daily for a maximum of 16 weeks or transition to maintenance dose. Discontinue therapy if inadequate response achieved after 16 weeks using 10 mg twice daily.

Maintenance: 5 mg twice daily; if patient experiences loss of response on 5 mg twice daily, then use 10 mg twice daily after assessing the benefits and risks and use for the shortest duration; use lowest effective dose to maintain response.

ER tablet:

Induction: 22 mg once daily for at least 8 weeks; based on therapeutic response, may continue 22 mg once daily for a maximum of 16 weeks or transition to maintenance dose. Discontinue therapy if inadequate response achieved after 16 weeks using 22 mg once daily.

Maintenance: 11 mg once daily; if patient experiences loss of response on 11 mg once daily, then use 22 mg once daily after assessing the benefits and risks and use for the shortest duration; use lowest effective dose to maintain response.

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Adult

The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.

Tofacitinib Dose Adjustments in Altered Kidney Functiona

a Krishnaswami 2014; manufacturer’s labeling.

Immediate release: Oral

Extended release: Oral

If the recommended dose is 5 mg twice daily

If the recommended dose is 10 mg twice daily

If the recommended dose is 11 mg once daily

If the recommended dose is 22 mg once daily

CrCl ≥60 mL/minute

No dosage adjustment necessary.

No dosage adjustment necessary.

No dosage adjustment necessary.

No dosage adjustment necessary.

CrCl <60 mL/minute

5 mg once daily.

5 mg twice daily.

Transition to immediate release 5 mg once daily.

11 mg once daily.

Augmented renal clearance (measured urinary CrCl ≥130 mL/minute/1.73 m2): Augmented renal clearance (ARC) is a condition that occurs in certain critically ill patients without organ dysfunction and with normal SCr concentrations. Younger patients (<55 years of age) admitted post trauma or major surgery are at highest risk for ARC, as well as those with sepsis, burns, or hematologic malignancies. An 8- to 24-hour measured urinary CrCl is necessary to identify these patients (Ref).

Oral: No data available. No dosage adjustment necessary (Ref).

Hemodialysis, intermittent (thrice weekly): Not significantly dialyzable (extraction ratio 0.73, but fraction of total elimination low due to significant nonrenal clearance):

Oral: Dose as for CrCl <60 mL/minute. When scheduled dose falls on dialysis days, administer after dialysis session; if dose given prior to dialysis, a supplemental dose is not necessary after the dialysis session (Ref).

Peritoneal dialysis: Oral: No data available; dose as for CrCl <60 mL/minute (Ref).

CRRT: Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Recommendations are based on high-flux dialyzers and effluent flow rates of 20 to 25 mL/kg/hour (or ~1,500 to 3,000 mL/hour) and minimal residual kidney function unless otherwise noted.

Oral: No data available; dose as for CrCl <60 mL/minute (Ref).

PIRRT (eg, sustained, low-efficiency diafiltration): Oral: No data available; dose as for CrCl <60 mL/minute. When scheduled dose falls on PIRRT days, administer after PIRRT session; if dose given prior to PIRRT, a supplemental dose is not necessary after the PIRRT session (Ref).

Dosing: Liver Impairment: Adult

Mild impairment: No dosage adjustment necessary.

Moderate impairment:

IR tablet: Reduce dose to 5 mg twice daily (if taking 10 mg twice daily) or 5 mg once daily (if taking 5 mg twice daily).

ER tablet: Reduce dose to 11 mg once daily (if taking 22 mg once daily) or transition to immediate release 5 mg once daily (if taking 11 mg once daily).

Severe impairment: Use is not recommended (has not been studied in patients with severe hepatic impairment or in patients with hepatitis B or hepatitis C viruses).

Adverse Reactions (Significant): Considerations
Bone marrow suppression

Lymphocytopenia (after an initial lymphocytosis), neutropenia, and anemia have been observed with tofacitinib therapy. Thrombocytopenia has also been reported (Ref). In an open-label long-term extension study over 9.5 years, potentially life-threatening lymphocytopenia (<500 cells/mm3) occurred in ~1% of patients; <1% of these patients developed serious infections. Moderate to severe neutropenia occurred in ~1% and <1% of patients, respectively; no patients developed serious infections (Ref). In another study, <1% of patients experienced a clinically significant decrease in hemoglobin (defined as a ≥3 g/dL decrease from baseline or hemoglobin ≤7 g/dL) (Ref). Cell counts typically stabilize with continued treatment; for cases requiring discontinuation, partial or complete resolution usually occurred (Ref).

Mechanism: Dose-related; may impair pro-growth signaling in bone marrow stem cells (Ref).

Onset: Delayed. Lymphocytopenia: Increases in lymphocyte counts in the first 3 months, followed by decreases for up to 48 months. Neutropenia: Decreases in the first 24 months (Ref).

Risk factors:

• Higher doses (Ref)

Cardiovascular events

Data regarding risk of major cardiovascular events (MACE) with tofacitinib are unclear. In a long-term open-label extension study over 9.5 years, the rate of cardiovascular events was low (Ref). Another study over a median follow-up of 4 years found an increased risk of MACE (including acute myocardial infarction and cerebrovascular accident) in patients ≥50 years of age with rheumatoid arthritis (RA) receiving tofacitinib (Ref). However, in a large registry of patients with RA, the rate of MACE was similar to patients receiving biological disease-modifying drugs (DMARDs) (Ref), and a World Health Organization database also failed to find an association (Ref).

Mechanism: Unknown; although, tofacitinib increases lipid levels by reducing cholesterol ester metabolism (Ref).

Risk factors:

• Age ≥65 years (Ref)

• Cardiovascular risk factors (eg, current or former smokers)

GI perforation

Gastrointestinal (GI) perforation has been reported, typically secondary to diverticulitis, and may be life-threatening. Most perforations have occurred in the lower GI tract (Ref).

Onset: Varied; may occur weeks to years after initiation (Ref).

Risk factors:

• Older age (Ref)

• Concurrent glucocorticoids (ie, prednisone ≥7.5 mg/day) or nonsteroidal anti-inflammatory drugs (Ref)

• History of diverticulitis/other GI conditions (Ref)

Hepatic effects

Increased liver enzymes may occur, which are usually mild and transient and may result in dose adjustment or discontinuation (Ref). Hepatotoxicity has also been reported (Ref).

Mechanism: Unknown, dose-related; metabolized in the liver through the CYP 3A4 pathway. Hepatotoxicity may be related to the production of a toxic or immunogenic intermediate (Ref).

Risk factors:

• Higher doses (Ref)

• Concurrent use of conventional synthetic disease modifying antirheumatic drugs (Ref)

Infection

Patients receiving tofacitinib are at increased risk for infection (including serious infection), which may result in hospitalization and/or fatality. Infections may present as disseminated (rather than local) disease. Active tuberculosis (including disseminated), invasive fungal infection (including cryptococcosis and pneumocystosis), bacterial infection, viral infection, or other opportunistic infection have been reported. Nasopharyngitis, upper respiratory tract infections, and urinary tract infections are the most common infections (Ref). Other infections, including appendicitis, cellulitis, diverticulitis of the gastrointestinal tract, herpes zoster infections (including disseminated cutaneous, meningoencephalitis, ophthalmologic) and reactivation of hepatitis B virus have also been reported. One study over a median follow-up of 4 years found an increased risk of infections in patients ≥50 years of age with rheumatoid arthritis (RA) receiving tofacitinib compared to patients receiving tumor necrosis factor inhibitors (Ref). In additional studies in patients with RA, the incidence of herpes zoster in patients receiving tofacitinib was more than twice that in patients receiving biological disease modifying drugs (DMARDs) (Ref).

Mechanism: Dose-related; may impair lymphocyte function, leading to suppression of immune response and increased risk of infection (Ref).

Onset: Delayed; median exposure prior to diagnosis of an opportunistic infection was 8 months (range: ~40 days to ~2 years).

Risk factors:

• Higher doses (Ref)

• Older age (Ref)

• Concurrent immunosuppressants (eg, corticosteroids, conventional synthetic DMARDS (Ref)

• Asian ethnicity (for herpes zoster) (Ref)

• Females (Ref)

• Lymphocytopenia (<500 cells/mm3) (Ref)

• History of an opportunistic infection

• Chronic or recurrent infection

• Conditions that predispose to infections (eg, advanced or poorly controlled diabetes)

• Residence/travel in areas of endemic tuberculosis or mycoses (blastomycosis, coccidioidomycosis, histoplasmosis)

Malignancy

Malignant neoplasm, including malignant lymphoma and malignant solid tumor, have occurred in patients treated with tofacitinib and other Janus kinase inhibitors for the treatment of inflammatory conditions. The most common types of malignancy observed were lung carcinoma, malignant neoplasm of the breast, gastric carcinoma, malignant neoplasm of colon or rectum, renal cell carcinoma, prostate carcinoma, malignant lymphoma, pancreatic adenocarcinoma, and malignant melanoma. One study over a median follow-up of 4 years found an increased risk of malignancies in patients ≥50 years of age with rheumatoid arthritis (RA) receiving tofacitinib compared to patients receiving tumor necrosis factor inhibitors (TNFi) (Ref). In contrast, no increase in risk of malignancies in general or of any specific type was detected compared to patients with RA receiving conventional synthetic disease modifying drugs (DMARDs) or with TNFi in earlier meta-analyses of randomized clinical trials (Ref). In two large registries of patients with RA, the rate of malignancy in patients receiving tofacitinib was similar to patients receiving biological DMARDs or with TNFi (Ref).

Mechanism: Not clearly established; may inhibit immunosurveillance to malignancy (Ref).

Risk factors:

• Age ≥65 years (Ref)

• Current or former smoker

Thrombosis

Thrombosis, including arterial thrombosis, deep vein thrombosis, and pulmonary embolism, have occurred in patients treated with tofacitinib and other Janus kinase (JAK) inhibitors used to treat inflammatory conditions. One study over a median follow-up of 4 years found an increased risk of venous thrombosis and pulmonary embolism in patients ≥50 years of age with rheumatoid arthritis (RA) receiving tofacitinib compared to patients receiving tumor necrosis factor inhibitors (TNFi) (Ref). However, in multiple large registries of patients with RA and other patients, the rate of thrombotic events with tofacitinib was low and similar to patients who used biological disease modifying drugs or TNFi (Ref).

Mechanism: Dose-related; JAK inhibition may affect a variety of pathways affecting endothelial activation and platelet aggregation (Kotyla 2021). Tofacitinib may also have off-target effects not related to JAK inhibition (Ref).

Risk factors:

• Higher doses (Ref)

• BMI ≥35 kg/m2 (Ref)

• History of chronic lung disease (Ref)

• Age ≥65 years (Ref)

• Prior venous thromboembolism (Ref)

Tuberculosis

Active tuberculosis (TB), which may present with pulmonary or extrapulmonary disease, has been reported. One study over a median follow-up of 4 years found an increased risk of TB in patients ≥50 years of age with rheumatoid arthritis (RA) receiving tofacitinib compared to patients receiving tumor necrosis factor inhibitors (Ref). In a meta-analysis of randomized clinical trials, the risk of TB in patients receiving tofacitinib at any dose was higher versus placebo but not statistically significant (Ref).

Mechanism: Dose-related; may impair lymphocyte function, leading to suppression of immune response and increased risk of infection (Ref).

Risk factors:

• Higher dose (Ref)

• Residence in an area with high TB prevalence

• Known TB exposure or ongoing risk factors for TB exposure (eg, travel to areas with high TB prevalence)

Adverse Reactions

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reaction incidence reported in adults. Incidences of adverse reactions may include unapproved dosing regimens and combination therapy.

>10%:

Endocrine & metabolic: Hyperlipidemia (including hypercholesterolemia [total: ≤9%], increased HDL cholesterol [10% to 12%], increased LDL cholesterol [15% to 19%], increased serum triglycerides [≤9%]).

Infection: Infection (20% to 22%; including bacterial infection, BK virus, cryptococcosis, cytomegalovirus disease, fungal infection, histoplasmosis, listeriosis, mycobacterium infection, opportunistic infection, reactivation of HBV, serious infection, tuberculosis [including disseminated], viral infection [and reactivation]) (table 1)

Tofacitinib: Adverse Reaction: Infection

Drug (Tofacitinib)

Placebo

Dose

Indication

Number of Patients (Tofacitinib)

Number of Patients (Placebo)

22%

18%

10 mg twice daily

Rheumatoid arthritis

1,349

809

20%

18%

5 mg twice daily

Rheumatoid arthritis

1,336

809

Respiratory: Nasopharyngitis (3% to 14%) (table 2)

Tofacitinib: Adverse Reaction: Nasopharyngitis

Drug (Tofacitinib)

Placebo

Dose

Indication

Number of Patients (Tofacitinib)

Number of Patients (Placebo)

4%

3%

5 mg twice daily

Rheumatoid arthritis

1,336

809

3%

3%

10 mg twice daily

Rheumatoid arthritis

1,349

809

14%

6%

10 mg twice daily

Ulcerative colitis

196

198

10%

6%

5 mg twice daily

Ulcerative colitis

198

198

1% to 10%:

Cardiovascular: Hypertension (2%)

Dermatologic: Acne vulgaris (≥2%), skin rash (6%)

Gastrointestinal: Diarrhea (3% to 5%), gastroenteritis (4%), nausea (4%)

Genitourinary: Urinary tract infection (2%)

Hematologic & oncologic: Anemia (2% to 4%) (table 3)

Tofacitinib: Adverse Reaction: Anemia

Drug (Tofacitinib)

Placebo

Dose

Indication

Number of Patients (Tofacitinib)

Number of Patients (Placebo)

4%

2%

5 mg twice daily

Ulcerative colitis

198

198

2%

2%

10 mg twice daily

Ulcerative colitis

196

198

Infection: Herpes zoster infection (1% to 5%; including disseminated cutaneous, meningoencephalitis, ophthalmologic) (table 4)

Tofacitinib: Adverse Reaction: Herpes Zoster Infection

Drug (Tofacitinib)

Placebo

Dose

Indication

Number of Patients (Tofacitinib)

Number of Patients (Placebo)

5%

1%

10 mg twice daily

Ulcerative colitis

196

198

1%

1%

5 mg twice daily

Ulcerative colitis

198

198

Nervous system: Headache (3% to 9%)

Neuromuscular & skeletal: Increased creatine phosphokinase in blood specimen (3% to 7%)

Respiratory: Upper respiratory tract infection (4% to 7%) (table 5)

Tofacitinib: Adverse Reaction: Upper Respiratory Tract Infection

Drug (Tofacitinib)

Placebo

Dose

Indication

Number of Patients (Tofacitinib)

Number of Patients (Placebo)

4%

3%

5 mg twice daily

Rheumatoid arthritis

1,336

809

4%

3%

10 mg twice daily

Rheumatoid arthritis

1,349

809

7%

4%

5 mg twice daily

Ulcerative colitis

198

198

6%

4%

10 mg twice daily

Ulcerative colitis

196

198

Miscellaneous: Fever (≥2%)

<1%: Hematologic & oncologic: Lymphocytopenia, neutropenia

Frequency not defined:

Cardiovascular: Peripheral edema

Dermatologic: Cellulitis, erythema of skin, pruritus

Endocrine & metabolic: Dehydration

Gastrointestinal: Abdominal pain, appendicitis, diverticulitis of the gastrointestinal tract, dyspepsia, esophageal candidiasis, gastritis, vomiting

Hepatic: Liver steatosis

Nervous system: Fatigue, insomnia, paresthesia

Neuromuscular & skeletal: Arthralgia, joint swelling, musculoskeletal pain, tendinopathy

Renal: Increased serum creatinine

Respiratory: Cough, dyspnea, infection due to an organism in genus Pneumocystis, interstitial lung disease, paranasal sinus congestion

Postmarketing:

Cardiovascular: Acute myocardial infarction (FDA 2021), arterial thrombosis (Mease 2020), deep vein thrombosis (Mease 2020), pulmonary embolism (Mease 2020), thrombosis (FDA 2019), venous thrombosis (Mease 2020)

Dermatologic: Malignant melanoma, psoriasiform eruption (Erol 2019), skin carcinoma (nonmelanoma) (Ytterberg 2022)

Endocrine & metabolic: Weight gain (Shah 2023)

Gastrointestinal: Gastrointestinal perforation (Xie 2016), malignant neoplasm of colon or rectum, pancreatic adenocarcinoma

Genitourinary: Malignant neoplasm of breast, prostate carcinoma

Hematologic & oncologic: Eosinophilia (Archer 2023), gastric carcinoma, Kaposi sarcoma (Gallo Marin 2023), lymphocytosis (Wollenhaupt 2019), malignant lymphoma (Ytterberg 2022), malignant neoplasm (Ytterberg 2022), malignant solid tumor (Ytterberg 2022), thrombocytopenia (Kadoba 2020)

Hepatic: Hepatotoxicity (Magri 2021), increased liver enzymes (Magri 2021)

Hypersensitivity: Hypersensitivity reaction (including angioedema)

Nervous system: Cerebrovascular accident (FDA 2021), progressive multifocal leukoencephalopathy (PML-immune reconstitution inflammatory syndrome [PML-IRIS]) (Schwartzmann 2023)

Renal: Renal cell carcinoma

Respiratory: Lung carcinoma, pneumonia (Wollenhaupt 2019)

Contraindications

There are no contraindications listed in the manufacturer's US labeling.

Canadian labeling: Hypersensitivity to tofacitinib or any component of the formulation; severe hepatic impairment; pregnancy; breastfeeding.

Warnings/Precautions

Concerns related to adverse effects:

• Hypersensitivity: Hypersensitivity reactions, including angioedema and urticaria, have occurred; discontinue therapy and evaluate cause for serious reactions.

• Interstitial lung disease: Interstitial lung disease (ILD) has been reported; patients developing ILD were receiving concomitant therapy associated with ILD (eg, methotrexate). Use with caution in patients with risk/history of ILD (Xeljanz Canadian product monograph).

Disease-related concerns:

• Active infections: Do not initiate tofacitinib in patients with active infections, including localized infections.

• Hepatic impairment: Use with caution in patients with hepatic impairment; see "Dosing: Hepatic Impairment" for additional information.

• Lung disease: Patients with a history of chronic lung disease or those who develop interstitial lung disease may be more prone to infections; use with caution.

• Renal impairment: Use with caution in patients with renal impairment; see "Dosing: Altered Kidney Function" for additional information.

Concurrent drug therapy issues:

• Immunosuppressant medications: Tofacitinib should not be administered in combination with strong immunosuppressive medications (eg, azathioprine, tacrolimus, cyclosporine) due to the risk of additive immunosuppression; such combinations have not been studied in RA.

• Biologic disease-modifying antirheumatic drugs: Tofacitinib should not be administered in combination with biologic disease-modifying antirheumatic drugs.

Special populations:

• Asian patients: Use with caution in Asian patients; an increased incidence of adverse reactions (eg, herpes zoster, opportunistic infections, decreased WBC, interstitial lung disease, increased transaminases) has been observed (Wollenhaupt 2014; Xeljanz Canadian product monograph).

• Patients with rheumatic musculoskeletal disease undergoing hip or knee replacement surgery: Hold tofacitinib for at least 3 days prior to surgery to reduce infection risk; therapy can be restarted once surgical wound shows evidence of healing (eg, no swelling, erythema, or drainage), sutures/staples are removed, and no ongoing nonsurgical site infections (typically ~14 days to reduce infection risk) (ACR/AAHKS [Goodman 2022]).

Dosage form specific issues:

• Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol and/or sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol. Large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity ("gasping syndrome") in neonates. The "gasping syndrome" consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP ["Inactive" 1997]; CDC 1982). Some data suggest that benzoate displaces bilirubin from protein-binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol and/or benzyl alcohol derivative with caution in neonates. See manufacturer's labeling.

• Extended release: Use caution when administering the ER formulation to patients with preexisting severe GI narrowing (pathologic or iatrogenic). There have been rare reports of obstructive symptoms in patients with known strictures following ingestion of other medications that also utilize a nondeformable ER formulation. The inert tablet shell of the ER tablet may be noticeable in the stool (or colostomy); the active medication will have been already absorbed.

• Non-interchangeability of dosage forms: ER tablets are not interchangeable or substitutable with the oral solution.

Other warnings/precautions:

• Immunizations: Immunization status should be current before initiating therapy. Live vaccines should not be given concomitantly with tofacitinib; recommended interval between receipt of live vaccines and initiation of immunosuppressive agents, such as tofacitinib, should follow current vaccination clinical guidelines. Dissemination of the vaccine strain of varicella zoster virus has been reported in a varicella virus-naive patient 16 days following vaccination with Zostavax (live attenuated zoster) and 2 days after the initiation of tofacitinib.

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Solution, Oral, as citrate [strength expressed as base]:

Xeljanz: 1 mg/mL (240 mL) [contains sodium benzoate]

Tablet, Oral, as citrate [strength expressed as base]:

Xeljanz: 5 mg

Xeljanz: 10 mg [contains fd&c blue #1 (brill blue) aluminum lake, fd&c blue #2 (indigotine,indigo carmine)]

Tablet Extended Release 24 Hour, Oral, as citrate [strength expressed as base]:

Xeljanz XR: 11 mg

Xeljanz XR: 22 mg [contains fd&c blue #2 (indigo carm) aluminum lake]

Generic Equivalent Available: US

No

Pricing: US

Solution (Xeljanz Oral)

1 mg/mL (per mL): $24.29

Tablet, 24-hour (Xeljanz XR Oral)

11 mg (per each): $242.93

22 mg (per each): $242.93

Tablets (Xeljanz Oral)

5 mg (per each): $121.46

10 mg (per each): $121.46

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Tablet, Oral, as citrate [strength expressed as base]:

Xeljanz: 5 mg

Xeljanz: 10 mg [contains fd&c blue #1 (brill blue) aluminum lake, fd&c blue #2 (indigo carm) aluminum lake]

Generic: 5 mg, 10 mg

Tablet Extended Release 24 Hour, Oral, as citrate [strength expressed as base]:

Xeljanz XR: 11 mg

Prescribing and Access Restrictions

Available through specialty/network pharmacies. Further information may be obtained from the manufacturer, Pfizer Inc, at 1-855-493-5526 or at http://www.xeljanz.com/.

Administration: Pediatric

Oral: Oral solution, immediate-release tablets: May be taken with or without food.

Oral solution: Use provided bottle adapter to attach oral syringe. After each use store bottle in carton to protect from light, rinse oral syringe with water, and allow to air dry. Discard any remaining oral solution 60 days after opening bottle.

Administration: Adult

Oral: May be taken with or without food.

Extended release: Swallow tablet whole and intact; do not crush, split, or chew.

Bariatric surgery: Some institutions may have specific protocols that conflict with these recommendations; refer to institutional protocols as appropriate. IR tablet formulation is available. If safety and efficacy can be effectively monitored, no change in formulation or administration is required after bariatric surgery.

Hazardous Drugs Handling Considerations

Hazardous agent (NIOSH 2024 [table 2]).

Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations and institution-specific policies/procedures for appropriate containment strategy (NIOSH 2023; NIOSH 2024; USP-NF 2020).

Note: Facilities may perform risk assessment of some hazardous drugs to determine if appropriate for alternative handling and containment strategies (USP-NF 2020). Refer to institution-specific handling policies/procedures.

Storage/Stability

Oral solution: Store in original container at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C and 30°C (59°F and 86°F). Protect from light. Discard any unused amount 60 days after opening.

Tablets: Store at 20°C to 25°C (68°F to 77°F).

Medication Guide and/or Vaccine Information Statement (VIS)

An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:

Xeljanz, Xeljanz XR: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/203214s038,208246s025,213082s010lbl.pdf#page=66

Use

Treatment of active polyarticular course juvenile idiopathic arthritis (Oral solution, immediate-release [IR] tablet: FDA approved in pediatric patients ≥2 years); treatment of active psoriatic arthritis in patients who have had an inadequate response or are intolerant to methotrexate or other disease-modifying antirheumatic drugs (DMARDs) (Tablets [IR/extended-release (ER)]: FDA approved in adults); treatment of moderately to severely active rheumatoid arthritis in patients who have had an inadequate response to or are intolerant to methotrexate (Tablets [IR/ER]: FDA approved in adults); treatment of moderately to severely acute ulcerative colitis in patients who have had an inadequate response to or are intolerant to tumor necrosis factor blockers (Tablets [IR/ER]: FDA approved in adults).

Metabolism/Transport Effects

Substrate of CYP2C19 (Minor), CYP3A4 (Major); Note: Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the drug interactions program by clicking on the “Launch drug interactions program” link above.

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the drug interactions program

Abrocitinib: May increase immunosuppressive effects of Immunosuppressants (Therapeutic Immunosuppressant Agents). Risk X: Avoid

Anifrolumab: Biologic Disease-Modifying Antirheumatic Drugs may increase immunosuppressive effects of Anifrolumab. Risk X: Avoid

Baricitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may increase immunosuppressive effects of Baricitinib. Risk X: Avoid

BCG Products: Immunosuppressants (Therapeutic Immunosuppressant Agents) may decrease therapeutic effects of BCG Products. Immunosuppressants (Therapeutic Immunosuppressant Agents) may increase adverse/toxic effects of BCG Products. Specifically, the risk of vaccine-associated infection may be increased. Risk X: Avoid

Brincidofovir: Immunosuppressants (Therapeutic Immunosuppressant Agents) may decrease therapeutic effects of Brincidofovir. Risk C: Monitor

Brivudine: May increase adverse/toxic effects of Immunosuppressants (Therapeutic Immunosuppressant Agents). Risk X: Avoid

Chikungunya Vaccine (Live): Immunosuppressants (Therapeutic Immunosuppressant Agents) may increase adverse/toxic effects of Chikungunya Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may decrease therapeutic effects of Chikungunya Vaccine (Live). Risk X: Avoid

Cladribine: Immunosuppressants (Therapeutic Immunosuppressant Agents) may increase immunosuppressive effects of Cladribine. Risk X: Avoid

Clofazimine: May increase serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Risk C: Monitor

Coccidioides immitis Skin Test: Coadministration of Immunosuppressants (Therapeutic Immunosuppressant Agents) and Coccidioides immitis Skin Test may alter diagnostic results. Management: Consider discontinuing therapeutic immunosuppressants several weeks prior to coccidioides immitis skin antigen testing to increase the likelihood of accurate diagnostic results. Risk D: Consider Therapy Modification

Corticosteroids (Systemic): May increase immunosuppressive effects of Tofacitinib. Management: Coadministration of tofacitinib with potent immunosuppressants is not recommended. Doses equivalent to more than 2 mg/kg or 20 mg/day of prednisone (for persons over 10 kg) administered for 2 or more weeks are considered immunosuppressive. Risk D: Consider Therapy Modification

COVID-19 Vaccines: Tofacitinib may decrease therapeutic effects of COVID-19 Vaccines. Management: Rheumatology guidelines recommend holding baricitinib, tofactinib, or upadacitinib for 1 to 2 weeks after vaccine administration as permitted by the underlying disease. Risk D: Consider Therapy Modification

CYP3A4 Inducers (Moderate): May decrease serum concentration of Tofacitinib. Risk C: Monitor

CYP3A4 Inducers (Strong): May decrease serum concentration of Tofacitinib. Risk X: Avoid

CYP3A4 Inhibitors (Moderate): May increase serum concentration of Tofacitinib. Risk C: Monitor

CYP3A4 Inhibitors (Strong): May increase serum concentration of Tofacitinib. Management: Tofacitinib dose reductions are recommended when combined with strong CYP3A4 inhibitors. Recommended dose adjustments vary by tofacitinib formulation and therapeutic indication. See full Lexi Interact monograph for details. Risk D: Consider Therapy Modification

Dengue Tetravalent Vaccine (Live): Immunosuppressants (Therapeutic Immunosuppressant Agents) may decrease therapeutic effects of Dengue Tetravalent Vaccine (Live). Immunosuppressants (Therapeutic Immunosuppressant Agents) may increase adverse/toxic effects of Dengue Tetravalent Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Risk X: Avoid

Denosumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may increase immunosuppressive effects of Denosumab. Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and immunosuppressants. If combined, monitor for signs/symptoms of serious infections. Risk D: Consider Therapy Modification

Deucravacitinib: May increase immunosuppressive effects of Immunosuppressants (Therapeutic Immunosuppressant Agents). Risk X: Avoid

Etrasimod: May increase immunosuppressive effects of Immunosuppressants (Therapeutic Immunosuppressant Agents). Risk X: Avoid

Filgotinib: May increase immunosuppressive effects of Immunosuppressants (Therapeutic Immunosuppressant Agents). Risk X: Avoid

Fluconazole: May increase serum concentration of Tofacitinib. Management: Tofacitinib dose reductions are recommended when combined with fluconazole. Recommended dose adjustments vary by tofacitinib formulation and therapeutic indication. See full Lexi Interact monograph for details. Risk D: Consider Therapy Modification

Fusidic Acid (Systemic): May increase serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Consider avoiding this combination if possible. If required, monitor patients closely for increased adverse effects of the CYP3A4 substrate. Risk D: Consider Therapy Modification

Grapefruit Juice: May increase serum concentration of Tofacitinib. Risk C: Monitor

Immunosuppressants (Cytotoxic Chemotherapy): May increase immunosuppressive effects of Tofacitinib. Risk X: Avoid

Immunosuppressants (Miscellaneous Oncologic Agents): May increase immunosuppressive effects of Tofacitinib. Risk X: Avoid

Immunosuppressants (Therapeutic Immunosuppressant Agents): May increase immunosuppressive effects of Tofacitinib. Management: Coadministration of tofacitinib with potent immunosuppressants is not recommended. Use with non-biologic disease-modifying antirheumatic drugs (DMARDs) was permitted in psoriatic arthritis clinical trials. Risk X: Avoid

Influenza Virus Vaccines: Immunosuppressants (Therapeutic Immunosuppressant Agents) may decrease therapeutic effects of Influenza Virus Vaccines. Management: Administer influenza vaccines at least 2 weeks prior to initiating immunosuppressants if possible. If vaccination occurs less than 2 weeks prior to or during therapy, revaccinate 2 to 3 months after therapy discontinued if immune competence restored. Risk D: Consider Therapy Modification

Methotrexate: May increase immunosuppressive effects of Tofacitinib. Management: Concomitant use of tofacitinib with high-dose or IV methotrexate is not recommended. Use with antirheumatic doses of methotrexate is permitted, and if combined, patients should be monitored for infection. Risk D: Consider Therapy Modification

Mumps- Rubella- or Varicella-Containing Live Vaccines: Immunosuppressants (Therapeutic Immunosuppressant Agents) may decrease therapeutic effects of Mumps- Rubella- or Varicella-Containing Live Vaccines. Immunosuppressants (Therapeutic Immunosuppressant Agents) may increase adverse/toxic effects of Mumps- Rubella- or Varicella-Containing Live Vaccines. Specifically, the risk of vaccine-associated infection may be increased. Risk X: Avoid

Nadofaragene Firadenovec: Immunosuppressants (Therapeutic Immunosuppressant Agents) may increase adverse/toxic effects of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased. Risk X: Avoid

Natalizumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may increase immunosuppressive effects of Natalizumab. Risk X: Avoid

Pidotimod: Immunosuppressants (Therapeutic Immunosuppressant Agents) may decrease therapeutic effects of Pidotimod. Risk C: Monitor

Pimecrolimus: Immunosuppressants (Therapeutic Immunosuppressant Agents) may increase immunosuppressive effects of Pimecrolimus. Risk X: Avoid

Pneumococcal Vaccines: Immunosuppressants (Therapeutic Immunosuppressant Agents) may decrease therapeutic effects of Pneumococcal Vaccines. Risk C: Monitor

Poliovirus Vaccine (Live/Trivalent/Oral): Immunosuppressants (Therapeutic Immunosuppressant Agents) may decrease therapeutic effects of Poliovirus Vaccine (Live/Trivalent/Oral). Immunosuppressants (Therapeutic Immunosuppressant Agents) may increase adverse/toxic effects of Poliovirus Vaccine (Live/Trivalent/Oral). Specifically, the risk of vaccine-associated infection may be increased. Risk X: Avoid

Polymethylmethacrylate: Immunosuppressants (Therapeutic Immunosuppressant Agents) may increase hypersensitivity effects of Polymethylmethacrylate. Management: Use caution when considering use of bovine collagen-containing implants such as the polymethylmethacrylate-based Bellafill brand implant in patients who are receiving immunosuppressants. Consider use of additional skin tests prior to administration. Risk D: Consider Therapy Modification

Rabies Vaccine: Immunosuppressants (Therapeutic Immunosuppressant Agents) may decrease therapeutic effects of Rabies Vaccine. Management: Complete rabies vaccination at least 2 weeks before initiation of immunosuppressant therapy if possible. If combined, check for rabies antibody titers, and if vaccination is for post exposure prophylaxis, administer a 5th dose of the vaccine. Risk D: Consider Therapy Modification

Ritlecitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may increase immunosuppressive effects of Ritlecitinib. Risk X: Avoid

Ruxolitinib (Topical): Immunosuppressants (Therapeutic Immunosuppressant Agents) may increase immunosuppressive effects of Ruxolitinib (Topical). Risk X: Avoid

Sipuleucel-T: Immunosuppressants (Therapeutic Immunosuppressant Agents) may decrease therapeutic effects of Sipuleucel-T. Management: Consider reducing the dose or discontinuing the use of immunosuppressants prior to initiating sipuleucel-T therapy. Risk D: Consider Therapy Modification

Tacrolimus (Topical): Immunosuppressants (Therapeutic Immunosuppressant Agents) may increase immunosuppressive effects of Tacrolimus (Topical). Risk X: Avoid

Talimogene Laherparepvec: Immunosuppressants (Therapeutic Immunosuppressant Agents) may increase adverse/toxic effects of Talimogene Laherparepvec. Specifically, the risk of infection from the live, attenuated herpes simplex virus contained in talimogene laherparepvec may be increased. Risk X: Avoid

Tertomotide: Immunosuppressants (Therapeutic Immunosuppressant Agents) may decrease therapeutic effects of Tertomotide. Risk X: Avoid

Typhoid Vaccine: Immunosuppressants (Therapeutic Immunosuppressant Agents) may decrease therapeutic effects of Typhoid Vaccine. Immunosuppressants (Therapeutic Immunosuppressant Agents) may increase adverse/toxic effects of Typhoid Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Risk X: Avoid

Upadacitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may increase immunosuppressive effects of Upadacitinib. Risk X: Avoid

Vaccines (Live): Immunosuppressants (Therapeutic Immunosuppressant Agents) may decrease therapeutic effects of Vaccines (Live). Immunosuppressants (Therapeutic Immunosuppressant Agents) may increase adverse/toxic effects of Vaccines (Live). Specifically, the risk of vaccine-associated infection may be increased. Risk X: Avoid

Vaccines (Non-Live/Inactivated/Non-Replicating): Immunosuppressants (Therapeutic Immunosuppressant Agents) may decrease therapeutic effects of Vaccines (Non-Live/Inactivated/Non-Replicating). Management: Give non-live/inactivated/non-replicating vaccines at least 2 weeks prior to starting immunosuppressants when possible. Patients vaccinated less than 14 days before or during therapy should be revaccinated at least 2 to 3 months after therapy is complete. Risk D: Consider Therapy Modification

Yellow Fever Vaccine: Immunosuppressants (Therapeutic Immunosuppressant Agents) may decrease therapeutic effects of Yellow Fever Vaccine. Immunosuppressants (Therapeutic Immunosuppressant Agents) may increase adverse/toxic effects of Yellow Fever Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Risk X: Avoid

Zoster Vaccine (Live/Attenuated): Immunosuppressants (Therapeutic Immunosuppressant Agents) may increase adverse/toxic effects of Zoster Vaccine (Live/Attenuated). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may decrease therapeutic effects of Zoster Vaccine (Live/Attenuated). Risk X: Avoid

Reproductive Considerations

Recommendations for use of tofacitinib to treat rheumatic and musculoskeletal diseases in patients planning to become pregnant or who are planning to father a child are not available due to lack of data (ACR [Sammaritano 2020]).

Agents other than tofacitinib are preferred to treat inflammatory bowel disease in patients planning to become pregnant. Disease management should be optimized prior to pregnancy. Tofacitinib should be avoided or used with caution prior to a planned pregnancy; discontinue 1 week prior to conception to limit first trimester fetal exposure (Mahadevan 2019).

Pregnancy Considerations

Tofacitinib crosses the placenta (Eliesen 2024; Mitrova 2024).

Outcome data following tofacitinib exposure during pregnancy are limited (Arzivian 2024; Chaparro 2024; Clowse 2016; Ernest-Suarez 2024; Fernández-Sánchez 2021; Mahadevan 2018; Mitrova 2024; Rowan 2024; Zhang 2024).

Recommendations for use of tofacitinib in pregnant patients with rheumatic and musculoskeletal diseases are not available due to lack of data (ACR [Sammaritano 2020]).

Inflammatory bowel disease is associated with adverse pregnancy outcomes, including an increased risk of miscarriage, premature delivery, delivery of a low-birth-weight infant, and poor maternal weight gain. Management of maternal disease should be optimized prior to pregnancy. Treatment decreases disease flares, disease activity, and the incidence of adverse pregnancy outcomes. When treatment for inflammatory bowel disease is needed in pregnant patients, use of tofacitinib should be avoided at least during the first trimester (Mahadevan 2019).

Tofacitinib is under study for the treatment of COVID-19 (NIH 2024). The risk of severe morbidity and mortality from COVID-19 infection is increased in pregnant patients compared to nonpregnant patients. Pregnant and recently pregnant patients with moderate or severe infection are at increased risk of complications such as hypertensive disorders of pregnancy, postpartum hemorrhage, or other infections compared to pregnant patients without COVID-19. Pregnant patients with symptoms may require ICU admission, mechanical ventilation, or ventilatory support (extracorporeal membrane oxygenation). Other adverse pregnancy outcomes include preterm birth and stillbirth. The risk of coagulopathy, cesarean delivery, and maternal death may be increased; neonates have an increased risk for NICU admission. Maternal age and comorbidities such as diabetes, hypertension, lung disease, and obesity may also increase the risk of severe illness in pregnant and recently pregnant patients (ACOG 2023; NIH 2024).

In general, the treatment of COVID-19 infection during pregnancy is the same as in nonpregnant patients. However, because data for most therapeutic agents in pregnant patients are limited, treatment options should be evaluated as part of a shared decision-making process. Use of an agent other than tofacitinib may be preferred (NIH 2024). Information related to the treatment of COVID-19 during pregnancy continues to emerge; refer to current guidelines for the treatment of pregnant patients.

Monitoring Parameters

Lymphocyte count (baseline and every 3 months thereafter); neutrophil/platelet counts (baseline, after 4 to 8 weeks, and every 3 months thereafter); hemoglobin (baseline, after 4 to 8 weeks, and every 3 months thereafter); lipids (4 to 8 weeks after therapy initiation and periodically); LFTs; signs and symptoms of infections (including tuberculosis) during and after therapy; abdominal symptoms; skin examinations (periodically, in patients at increased risk for skin cancer); heart rate and blood pressure at baseline and periodically thereafter.

Mechanism of Action

Tofacitinib inhibits Janus kinase (JAK) enzymes, which are intracellular enzymes involved in stimulating hematopoiesis and immune cell function through a signaling pathway. In response to extracellular cytokine or growth factor signaling, JAKs activate signal transducers and activators of transcription (STATs), which regulate gene expression and intracellular activity. Inhibition of JAKs prevents cytokine- or growth factor-mediated gene expression and intracellular activity of immune cells, reduces circulating CD16/56+ natural killer cells, serum IgG, IgM, IgA, and C-reactive protein, and increases B cells.

Pharmacokinetics (Adult Data Unless Noted)

Absorption: Oral:

IR tablet: Rapid (74%); Cmax is reduced by 32% when administered with high-fat meal, but AUC remains unchanged.

Extended release: When administered with high-fat meal, Cmax,following an 11 mg and 22 mg dose, increased by 27% and 19%, respectively, and Tmax was extended by ~1 hour, but AUC remains unchanged.

Distribution: Vd: 87 L.

Bioavailability: The AUC and Cmax of 11 mg extended release once daily are equivalent to 5 mg IR tablet administered twice daily.

Protein binding: ~40% (predominantly to albumin).

Metabolism: Hepatic (70%): CYP3A4 and CYP2C19 to inactive metabolites.

Half-life elimination: ~3 hours (IR solution, tablet); ~6 to 8 hours (extended release).

Time to peak: 0.5 to 1 hour (IR solution, tablet); 4 hours (extended release).

Excretion: Primarily urine (30%) as unchanged drug.

Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)

Altered kidney function: AUC increased ~1.75- to 2.5-fold in moderate and severe renal impairment.

Hepatic function impairment: AUC and Cmax increased ~1.5-fold in moderate hepatic impairment.

Brand Names: International
International Brand Names by Country
For country code abbreviations (show table)

  • (AE) United Arab Emirates: Xeljanz;
  • (AR) Argentina: Atexa | Intrart | Janvax | Klaxon | Modismune | Modismune lp | Rofek | Rofek xr | Terfanib | Tofax | Tolvar | Xeljanz | Xeljanz XR;
  • (AT) Austria: Xeljanz;
  • (AU) Australia: Xeljanz;
  • (BD) Bangladesh: Arthanib | Arthanib xr | Jakloc | Jaktor | Tocit | Tofacent | Tofacinix | Tofacit | Tofacit xr | Tofanib | Tofatin | Tofator | Tofaxen | Tojak | Xelnib;
  • (BE) Belgium: Xeljanz;
  • (BG) Bulgaria: Xeljanz | Xeljanz XR;
  • (BR) Brazil: Xeljanz;
  • (CH) Switzerland: Xeljanz;
  • (CL) Chile: Xeljanz | Xeljanz XR;
  • (CO) Colombia: Xeljanz | Xeljanz XR;
  • (CZ) Czech Republic: Xeljanz;
  • (DE) Germany: Xeljanz;
  • (DO) Dominican Republic: Xeljanz | Xeljanz XR;
  • (EC) Ecuador: Janvax | Rofek | Rofek xr | Terfanib | Tofatis | Tofax | Tolvar | Xeljanz | Xeljanz XR;
  • (EE) Estonia: Xeljanz;
  • (EG) Egypt: Xeljanz | Xeljanz XR;
  • (ES) Spain: Xeljanz;
  • (FI) Finland: Xeljanz;
  • (FR) France: Xeljanz;
  • (GB) United Kingdom: Xeljanz;
  • (GR) Greece: Xeljanz;
  • (HK) Hong Kong: Xeljanz | Xeljanz XR;
  • (HR) Croatia: Xeljanz;
  • (HU) Hungary: Xeljanz;
  • (IE) Ireland: Xeljanz;
  • (IN) India: Aztofa | Aztofa xr | Betrecep | Evertop | Exnib | Exnib od | Getrid ra | Intajac | Intajac er | Jakauto | Jakmac | Jakmac er | Jaknat | Jakseas | Jakura | Novanib t | T jaki | T jaki xr | Tfct nib | Tiflet | Tnib | Tobraza | Tofabin | Tofadoz | Tofahenz | Tofajak | Tofajak xr | Tofakin | Tofakin er | Tofanta new | Tofanta xr | Tofashine | Tofashine xr | Tofastar | Tofasure | Tofatas | Tofatas xr | Tofaxen | Tofe | Tofe er | Tofza | Tonib | Tosanib | Tritonib | Xeljanz;
  • (IT) Italy: Xeljanz;
  • (JO) Jordan: Trijan | Xeljanz;
  • (JP) Japan: Xeljanz;
  • (KE) Kenya: Xeltin;
  • (KR) Korea, Republic of: Il yang tofacitinib | Topla | Tozelz | Xeljanz | Xeltoz;
  • (KW) Kuwait: Xeljanz;
  • (LB) Lebanon: Xeljanz | Xeljanz XR;
  • (LT) Lithuania: Xeljanz;
  • (LU) Luxembourg: Xeljanz;
  • (LV) Latvia: Xeljanz;
  • (MA) Morocco: Xeljanz;
  • (MX) Mexico: Xeljanz | Xeljanz XR;
  • (MY) Malaysia: Xeljanz;
  • (NG) Nigeria: Xeljanz;
  • (NL) Netherlands: Xeljanz;
  • (NO) Norway: Xeljanz;
  • (NZ) New Zealand: Tofacitinib | Xeljanz;
  • (PE) Peru: Xeljanz;
  • (PH) Philippines: Tofacitinib | Xeljanz | Xeljanz XR;
  • (PL) Poland: Xeljanz;
  • (PR) Puerto Rico: Xeljanz | Xeljanz XR;
  • (PT) Portugal: Xeljanz;
  • (PY) Paraguay: Xeljanz;
  • (QA) Qatar: Trijan | Xeljanz | Xeljanz XR;
  • (RO) Romania: Xeljanz;
  • (RU) Russian Federation: Jakvinus | Jaquinus | Tofacitinib;
  • (SA) Saudi Arabia: Xeljanz;
  • (SE) Sweden: Xeljanz;
  • (SG) Singapore: Xeljanz;
  • (SI) Slovenia: Xeljanz;
  • (SK) Slovakia: Xeljanz;
  • (TH) Thailand: Xeljanz;
  • (TN) Tunisia: Xeljanz;
  • (TR) Turkey: Jandark | Xeljanz | Xeljanz XR;
  • (TW) Taiwan: Xeljanz | Xeljanz XR;
  • (UA) Ukraine: Xeljanz;
  • (UG) Uganda: Jitrit | Xeltin;
  • (ZA) South Africa: Tofajak | Xeljanz | Xeljanz XR;
  • (ZW) Zimbabwe: Xeljanz
  1. Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. J Pediatr. 2001;139(2):317-319. doi:10.1067/mpd.2001.116281 [PubMed 11487763]
  2. American College of Obstetricians and Gynecologists (ACOG). COVID-19 FAQs for obstetricians-gynecologists, obstetrics. https://www.acog.org/clinical-information/physician-faqs/covid-19-faqs-for-ob-gyns-obstetrics. Accessed December 4, 2023.
  3. Anderson PO, Sauberan JB. Modeling drug passage into human milk. Clin Pharmacol Ther. 2016;100(1):42-52. doi:10.1002/cpt.377 [PubMed 27060684]
  4. Archer S, Ferreira D, Ferreira AT, et al. Tofacitinib-induced eosinophilia. Rev Esp Enferm Dig. 2023;115(12):742. doi:10.17235/reed.2023.9831/2023 [PubMed 37539549]
  5. Arzivian A, Zhang E, Laube R, Leong R. First-trimester exposure to tofacitinib in ulcerative colitis: a case report of a healthy newborn and literature review. Clin Case Rep. 2024;12(4):e8764. doi:10.1002/ccr3.8764 [PubMed 38617066]
  6. Bachelez H, van de Kerkhof PC, Strohal R, et al; OPT Compare Investigators. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial. Lancet. 2015;386(9993):552-561. doi:10.1016/S0140-6736(14)62113-9 [PubMed 26051365]
  7. Bhimraj A, Morgan RL, Shumaker AH, et al; Infectious Diseases Society of America. Infectious Diseases Society of America guidelines on the treatment and management of patients with COVID-19. https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/. Updated June 29, 2022. Accessed August 10, 2022.
  8. Bilbao-Meseguer I, Rodríguez-Gascón A, Barrasa H, Isla A, Solinís MÁ. Augmented renal clearance in critically ill patients: a systematic review. Clin Pharmacokinet. 2018;57(9):1107-1121. doi:10.1007/s40262-018-0636-7 [PubMed 29441476]
  9. Centers for Disease Control and Prevention (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. MMWR Morb Mortal Wkly Rep. 1982;31(22):290-291. http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm. [PubMed 6810084]
  10. Chaparro M, Ceballos D, Vicente R, Gisbert JP. Experience of tofacitinib use in pregnancy in patients with ulcerative colitis. Clin Drug Investig. 2024;44(4):285-288. doi:10.1007/s40261-024-01353-3 [PubMed 38499915]
  11. Charles-Schoeman C, Fleischmann R, Mysler E, et al. Risk of venous thromboembolism with tofacitinib versus tumor necrosis factor inhibitors in cardiovascular risk-enriched rheumatoid arthritis patients. Arthritis Rheumatol. 2024;76(8):1218-1229. doi:10.1002/art.42846 [PubMed 38481002]
  12. Clowse ME, Feldman SR, Isaacs JD, et al. Pregnancy outcomes in the tofacitinib safety databases for rheumatoid arthritis and psoriasis. Drug Saf. 2016;39(8):755-762. doi:10.1007/s40264-016-0431-z [PubMed 27282428]
  13. Cohen SB, Tanaka Y, Mariette X, et al. Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme. RMD Open. 2020;6(3):e001395. doi:10.1136/rmdopen-2020-001395 [PubMed 33127856]
  14. Curtis JR, Xie F, Yun H, Bernatsky S, Winthrop KL. Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis. Ann Rheum Dis. 2016;75(10):1843-1847. doi:10.1136/annrheumdis-2016-209131 [PubMed 27113415]
  15. Desai RJ, Pawar A, Khosrow-Khavar F, Weinblatt ME, Kim SC. Risk of venous thromboembolism associated with tofacitinib in patients with rheumatoid arthritis: a population-based cohort study. Rheumatology (Oxford). 2021;61(1):121-130. doi:10.1093/rheumatology/keab294 [PubMed 33752237]
  16. Desai RJ, Pawar A, Weinblatt ME, Kim SC. Comparative risk of venous thromboembolism in rheumatoid arthritis patients receiving tofacitinib versus those receiving tumor necrosis factor inhibitors: an Observational Cohort Study. Arthritis Rheumatol. 2019;71(6):892-900. doi:10.1002/art.40798 [PubMed 30552833]
  17. Eliesen GAM, Fransen M, van Hove H, van den Broek PHH, Greupink R. Placental transfer of tofacitinib in the ex vivo dual-side human placenta perfusion model. Curr Res Toxicol. 2024;6:100149. doi:10.1016/j.crtox.2024.100149 [PubMed 38292667]
  18. Ernest-Suarez K, Murguía-Favela LE, Novak KL, Panaccione R, Constantinescu C, Seow CH. Normal infant immunologic assessment and uneventful live rotavirus vaccination despite continuous tofacitinib exposure in utero and during breastfeeding. Crohns Colitis 360. 2024;6(1):otae006. doi:10.1093/crocol/otae006 [PubMed 38317692]
  19. Erol K, Ertaş R. Tofacitinib induced psoriasiform lesion in a patient with rheumatoid arthritis. Arch Rheumatol. 2019;35(3):440-442. doi:10.46497/ArchRheumatol.2020.7541 [PubMed 33458669]
  20. Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.
  21. Faquetti ML, Grisoni F, Schneider P, Schneider G, Burden AM. Identification of novel off targets of baricitinib and tofacitinib by machine learning with a focus on thrombosis and viral infection. Sci Rep. 2022;12(1):7843. doi:10.1038/s41598-022-11879-1 [PubMed 35551258]
  22. FDA Safety Alert. MedWatch. Xeljanz, Xeljanz XR (tofacitinib): Drug safety communication – due to an increased risk of blood clots and death with higher dose. Food and Drug Administration website. https://www.fda.gov/safety/medwatch-safety-alerts-human-medical-products/xeljanz-xeljanz-xr-tofacitinib-drug-safety-communication-due-increased-risk-blood-clots-and-death. Accessed August 5, 2019.
  23. Fernández-Sánchez M, Ribes-Artero H, Romá-Sánchez E, et al. Fetal exposure to tofacitinib during the first trimester: a healthy newborn case report. Birth Defects Res. 2021;113(17):1275-1279. doi:10.1002/bdr2.1942 [PubMed 34309233]
  24. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2021;73(7):924-939. doi:10.1002/acr.24596 [PubMed 34101387]
  25. Gallo Marin B, Maymone MBC, El Rayess F, Telang GH. Kaposi sarcoma associated with tofacitinib use in a patient with rheumatoid arthritis. R I Med J (2013). 2023;106(7):18-20. [PubMed 37494621]
  26. Goodman SM, Springer BD, Chen AF, et al. 2022 American College of Rheumatology/American Association of Hip and Knee Surgeons guideline for the perioperative management of antirheumatic medication in patients with rheumatic diseases undergoing elective total hip or total knee arthroplasty. Arthritis Care Res (Hoboken). 2022;74(9):1399-1408. doi:10.1002/acr.24893 [PubMed 35718887]
  27. Guimarães PO, Quirk D, Furtado RH, et al; STOP-COVID Trial Investigators. Tofacitinib in patients hospitalized with Covid-19 pneumonia. N Engl J Med. 2021;385(5):406-415. doi:10.1056/NEJMoa2101643 [PubMed 34133856]
  28. Harigai M. Growing evidence of the safety of JAK inhibitors in patients with rheumatoid arthritis. Rheumatology (Oxford). 2019;58(suppl 1):i34-i42. doi:10.1093/rheumatology/key287 [PubMed 30806708]
  29. Hodson L, Ovesen J, Couch J, et al; US Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health. Managing hazardous drug exposures: information for healthcare settings, 2023. https://doi.org/10.26616/NIOSHPUB2023130. Updated April 2023. Accessed December 27, 2024.
  30. Hoisnard L, Lebrun-Vignes B, Maury S, et al. Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database. Sci Rep. 2022;12(1):7140. doi:10.1038/s41598-022-10777-w [PubMed 35504889]
  31. Huang F, Luo ZC. Adverse drug events associated with 5mg versus 10mg tofacitinib (Janus kinase inhibitor) twice daily for the treatment of autoimmune diseases: a systematic review and meta-analysis of randomized controlled trials. Clin Rheumatol. 2019;38(2):523-534. doi:10.1007/s10067-018-4299-4 [PubMed 30242639]
  32. "Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. Pediatrics. 1997;99(2):268-278. doi:10.1542/peds.99.2.268 [PubMed 9024461]
  33. Ito S. Drug therapy for breast-feeding women. N Engl J Med. 2000;343(2):118-126. doi:10.1056/NEJM200007133430208 [PubMed 10891521]
  34. Ji X, Hu L, Wang Y, Man S, et al. Risk of tuberculosis in patients with rheumatoid arthritis treated with biological and targeted drugs: meta-analysis of randomized clinical trials. Chin Med J (Engl). 2022;135(4):409-415. doi:10.1097/CM9.0000000000001948 [PubMed 35194004]
  35. Julsgaard M, Mahadevan U, Vestergaard T, et al. Tofacitinib concentrations in plasma and breastmilk of a lactating woman with ulcerative colitis. Lancet Gastroenterol Hepatol. 2023;8(8):695-697. doi:10.1016/S2468-1253(23)00158-9 [PubMed 37269871]
  36. Kadoba K, Waki D, Nishimura K, et al. Development of severe thrombocytopenia with TAFRO syndrome-like features in a patient with rheumatoid arthritis treated with a Janus kinase inhibitor: a case report. Medicine (Baltimore). 2020;99(42):e22793. doi:10.1097/MD.0000000000022793 [PubMed 33080751]
  37. Khosrow-Khavar F, Desai RJ, Lee H, Lee SB, Kim SC. Tofacitinib and risk of malignancy: results from the Safety of Tofacitinib in Routine Care Patients With Rheumatoid Arthritis (STAR-RA) Study. Arthritis Rheumatol. 2022a;74(10):1648-1659. doi:10.1002/art.42250 [PubMed 35643956]
  38. Khosrow-Khavar F, Kim SC, Lee H, Lee SB, Desai RJ. Tofacitinib and risk of cardiovascular outcomes: results from the Safety of TofAcitinib in Routine care patients with Rheumatoid Arthritis (STAR-RA) study. Ann Rheum Dis. 2022b;81(6):798-804. doi:10.1136/annrheumdis-2021-221915 [PubMed 35027405]
  39. Kivitz AJ, Cohen S, Keystone E, et al. A pooled analysis of the safety of tofacitinib as monotherapy or in combination with background conventional synthetic disease-modifying antirheumatic drugs in a Phase 3 rheumatoid arthritis population. Semin Arthritis Rheum. 2018;48(3):406-415. doi:10.1016/j.semarthrit.2018.07.006 [PubMed 30177460]
  40. Kotyla PJ, Engelmann M, Giemza-Stokłosa J, Wnuk B, Islam MA. Thromboembolic adverse drug reactions in Janus Kinase (JAK) inhibitors: does the inhibitor specificity play a role? Int J Mol Sci. 2021;22(5):2449. doi:10.3390/ijms22052449 [PubMed 33671049]
  41. Kremer JM, Bingham CO 3rd, Cappelli LC, et al. Postapproval comparative safety study of tofacitinib and biological disease-modifying antirheumatic drugs: 5-year results from a United States-based Rheumatoid Arthritis Registry. ACR Open Rheumatol. 2021;3(3):173-184. doi:10.1002/acr2.11232 [PubMed 33570260]
  42. Krishnaswami S, Chow V, Boy M, Wang C, Chan G. Pharmacokinetics of tofacitinib, a janus kinase inhibitor, in patients with impaired renal function and end-stage renal disease. J Clin Pharmacol. 2014;54(1):46-52. doi:10.1002/jcph.178 [PubMed 24030917]
  43. Lam C, Ferguson ID, Mariano MC, et al. Repurposing tofacitinib as an anti-myeloma therapeutic to reverse growth-promoting effects of the bone marrow microenvironment. Haematologica. 2018;103(7):1218-1228. doi:10.3324/haematol.2017.174482 [PubMed 29622655]
  44. Lee EB, Yamanaka H, Liu Y, et al. Efficacy and safety of tofacitinib for the treatment of rheumatoid arthritis in patients from the Asia-Pacific region: post-hoc analyses of pooled clinical study data. Int J Rheum Dis. 2019;22(6):1094-1106. doi:10.1111/1756-185X.13516 [PubMed 30900375]
  45. Magrì S, Chessa L, Demurtas M, Cabras F, Mocci G. Review article: safety of new biologic agents for inflammatory bowel disease in the liver. Eur J Gastroenterol Hepatol. 2021;33(5):623-630. doi:10.1097/MEG.0000000000002076 [PubMed 33470695]
  46. Mahadevan U, Dubinsky MC, Su C, et al. Outcomes of pregnancies with maternal/paternal exposure in the tofacitinib safety databases for ulcerative colitis. Inflamm Bowel Dis. 2018;24(12):2494-2500. doi:10.1093/ibd/izy160 [PubMed 29982686]
  47. Mahadevan U, Robinson C, Bernasko N, et al. Inflammatory bowel disease in pregnancy clinical care pathway: a report from the American Gastroenterological Association IBD Parenthood Project Working Group. Gastroenterology. 2019;156(5):1508-1524. doi:10.1053/j.gastro.2018.12.022 [PubMed 30658060]
  48. Maneiro JR, Souto A, Gomez-Reino JJ. Risks of malignancies related to tofacitinib and biological drugs in rheumatoid arthritis: systematic review, meta-analysis, and network meta-analysis. Semin Arthritis Rheum. 201t;47(2):149-156. doi:10.1016/j.semarthrit.2017.02.007 [PubMed 28284845]
  49. Mease P, Charles-Schoeman C, Cohen S, et al. Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data. Ann Rheum Dis. 2020;79(11):1400-1413. doi:10.1136/annrheumdis-2019-216761 [PubMed 32759265]
  50. Menter A, Gelfand JM, Connor C, et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies. J Am Acad Dermatol. 2020;82(6):1445-1486. doi:10.1016/j.jaad.2020.02.044 [PubMed 32119894]
  51. Mitrova K, Julsgaard M, Augustijns P, Cerna K, Mahadevan U, Duricova D; Pregnancy Study Group. Tofacitinib in pregnancy: assessing pregnancy and infant outcomes, cord blood, and breast milk concentrations. Clin Gastroenterol Hepatol. 2024:S1542-3565(24)00096-X. doi:10.1016/j.cgh.2024.01.019 [PubMed 38309493]
  52. National Institutes of Health (NIH). COVID-19 Treatment Guidelines Panel. Coronavirus disease 2019 (COVID-19) treatment guidelines. https://www.covid19treatmentguidelines.nih.gov/. Updated August 8, 2022. Accessed August 9, 2022.
  53. National Institutes of Health (NIH). COVID-19 Treatment Guidelines Panel. Coronavirus disease 2019 (COVID-19) treatment guidelines. https://www.covid19treatmentguidelines.nih.gov/. Updated February 29, 2024. Accessed March 14, 2024.
  54. Ovesen JL, Sam­mons D, Connor TH, et al; US Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health. NIOSH list of hazardous drugs in healthcare settings, 2024. https://doi.org/10.26616/NIOSHPUB2025103. Updated December 18, 2024. Accessed December 20, 2024.
  55. Papp KA, Menter A, Strober B, et al. Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study. Br J Dermatol. 2012;167(3):668-677. doi:10.1111/j.1365-2133.2012.11168.x [PubMed 22924949]
  56. Papp KA, Menter MA, Abe M, et al; OPT Pivotal 1 and OPT Pivotal 2 investigators. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials. Br J Dermatol. 2015;173(4):949-961. doi:10.1111/bjd.14018 [PubMed 26149717]
  57. Refer to manufacturer's labeling.
  58. Robinette ML, Cella M, Telliez JB, et al. Jak3 deficiency blocks innate lymphoid cell development. Mucosal Immunol. 2018;11(1):50-60. doi:10.1038/mi.2017.38 [PubMed 28513593]
  59. Rowan C, Yeaman F, Ernest-Suarez K, et al. Tofacitinib as a rescue therapy for ulcerative colitis in pregnancy. Inflamm Bowel Dis. 2024;30(5):868-870. doi:10.1093/ibd/izae076 [PubMed 38591862]
  60. Sammaritano LR, Bermas BL, Chakravarty EE, et al. 2020 American College of Rheumatology guideline for the management of reproductive health in rheumatic and musculoskeletal diseases. Arthritis Rheumatol. 2020;72(4):529-556. doi:10.1002/art.41191 [PubMed 32090480]
  61. Schulze-Koops H, Strand V, Nduaka C, et al. Analysis of haematological changes in tofacitinib-treated patients with rheumatoid arthritis across phase 3 and long-term extension studies. Rheumatology (Oxford). 2017;56(1):46-57. doi:10.1093/rheumatology/kew329 [PubMed 28028154]
  62. Schwartzmann Y, Vaknin-Dembinsky A, Gomori JM, et al. Tofacitinib-induced progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome. Neurol Sci. 2023;44(10):3737-3739. doi:10.1007/s10072-023-06897-4 [PubMed 37306796]
  63. Shah K, Shukla D, Patel M, Malhotra S. A case series on tofacitinib-induced weight gain. Indian J Pharmacol. 2023;55(4):263-265. doi:10.4103/ijp.ijp_158_23 [PubMed 37737080]
  64. Solipuram V, Mohan A, Patel R, Ni R. Effect of janus kinase inhibitors and methotrexate combination on malignancy in patients with rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials. Auto Immun Highlights. 2021;12(1):8. doi:10.1186/s13317-021-00153-5 [PubMed 33910632]
  65. Udy AA, Roberts JA, Boots RJ, Paterson DL, Lipman J. Augmented renal clearance: implications for antibacterial dosing in the critically ill. Clin Pharmacokinet. 2010;49(1):1-16. doi:10.2165/11318140-000000000-00000 [PubMed 20000886]
  66. US Food and Drug Administration (FDA). FDA Safety Alert. MedWatch. Xeljanz, Xeljanz XR (tofacitinib): FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions. https://www.fda.gov/drugs/drug-safety-and-availability/fda-requires-warnings-about-increased-risk-serious-heart-related-events-cancer-blood-clots-and-death. Accessed September 2, 2021
  67. United States Pharmacopeia. <800> Hazardous Drugs—Handling in Healthcare Settings. In: USP-NF. United States Pharmacopeia; July 1, 2020. Accessed January 16, 2025. doi:10.31003/USPNF_M7808_07_01
  68. van Vollenhoven R, Lee EB, Strengholt S, et al. Evaluation of the short-, mid-, and long-term effects of tofacitinib on lymphocytes in patients with rheumatoid arthritis. Arthritis Rheumatol. 2019;71(5):685-695. doi:10.1002/art.40780 [PubMed 30427585]
  69. Winthrop KL, Yamanaka H, Valdez H, et al. Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis. Arthritis Rheumatol. 2014;66(10):2675-2684. doi:10.1002/art.38745 [PubMed 24943354]
  70. Wollenhaupt J, Lee EB, Curtis JR, et al. Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study. Arthritis Res Ther. 2019;21(1):89. doi:10.1186/s13075-019-1866-2 [PubMed 30953540]
  71. Wollenhaupt J, Silverfield J, Lee EB, et al. Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, long term extension studies. J Rheumatol. 2014;41(5):837-852. doi:10.3899/jrheum.130683 [PubMed 24692527]
  72. Xeljanz/Xeljanz XR (tofacitinib) [prescribing information]. New York, NY: Pfizer Inc; September 2024.
  73. Xeljanz/Xeljanz XR (tofacitinib) [product monograph]. Kirkland, Quebec, Canada: Pfizer Canada ULC; April 2024.
  74. Xie W, Yang X, Huang H, Gao D, Ji L, Zhang Z. Risk of malignancy with non-TNFi biologic or tofacitinib therapy in rheumatoid arthritis: A meta-analysis of observational studies. Semin Arthritis Rheum. 2020;50(5):930-937. doi:10.1016/j.semarthrit.2020.08.007 [PubMed 32906027]
  75. Xie F, Yun H, Bernatsky S, Curtis JR. Brief report: risk of gastrointestinal perforation among rheumatoid arthritis patients receiving tofacitinib, tocilizumab, or other biologic treatments. Arthritis Rheumatol. 2016;68(11):2612-2617. doi:10.1002/art.39761 [PubMed 27213279]
  76. Ytterberg SR, Bhatt DL, Mikuls TR, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med. 2022;386(4):316-326. doi:10.1056/NEJMoa2109927 [PubMed 35081280]
  77. Zhang C, Shi X, Ding Y, et al. Pregnancy outcomes following tofacitinib use for synovitis, acne, pustulosis, hyperostosis and osteitis syndrome: case report. Int J Rheum Dis. 2024;27(6):e15209. doi:10.1111/1756-185X.15209 [PubMed 38873853]
  78. Zyuz'kov GN, Zhdanov VV, Udut EV, et al. Involvement of JAK1, JAK2, and JAK3 in stimulation of functional activity of mesenchymal progenitor cells by fibroblast growth factor. Bull Exp Biol Med. 2016;162(2):240-243. doi:10.1007/s10517-016-3585-x [PubMed 27905037]
Topic 129936 Version 165.0